356 results on '"Smyth, Elizabeth C."'
Search Results
2. Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation
3. Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer
4. Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer
5. Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy
6. Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation
7. Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”
8. Multicentre validation of CT grey-level co-occurrence matrix features for overall survival in primary oesophageal adenocarcinoma.
9. UKIOG Cancer Update 2023
10. Serial ctDNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection
11. Gastric tumours
12. Mind the target: programmed death ligand 1 in oesophagogastric cancers
13. Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer
14. Correction: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy
15. Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy
16. Multimodality treatment for localized gastric cancer: state of the art and new insights
17. Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer
18. Management of rectal cancer in the era of total neoadjuvant therapy and watch and wait: A multidisciplinary team discussion at the Australasian Gastro‐Intestinal Trials Group (AGITG) Annual Scientific Meeting 2022
19. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial
20. Management of rectal cancer in the era of total neoadjuvant therapy and watch and wait: A multidisciplinary team discussion at the Australasian Gastro‐Intestinal Trials Group (AGITG) Annual Scientific Meeting 2022.
21. Retooling treatment in oligometastatic oesophageal cancer
22. Rationale for Immunotherapy in Gastrointestinal Malignancies
23. Gastric Cancers
24. List of Contributors
25. Emerging targets in gastroesophageal adenocarcinoma: what the future looks like
26. Should chemotherapy-free treatment be offered for advanced oesophageal squamous-cell carcinoma?
27. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
28. Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy Plus Surgery for Patients With Gastroesophageal Cancer—Is There Room for Improvement?
29. Two steps forward and one step back
30. Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma.
31. Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001–2010
32. Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?
33. The Preoperative Lymphocyte-to-Monocyte Ratio is Prognostic of Clinical Outcomes for Patients with Liver-Only Colorectal Metastases in the Neoadjuvant Setting
34. Combination immune checkpoint blockade in advanced untreated gastroesophageal adenocarcinoma: Seeking biomarkers for durable benefit
35. Combination immune checkpoint inhibition for older patients with oesophageal squamous cell cancer
36. Rearrangement processes and structural variations show evidence of selection in oesophageal adenocarcinomas
37. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial
38. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?
39. Immunotherapy for Squamous Esophageal Cancer: A Review
40. Gastric cancer
41. Targeting HER2 for localised oesophageal cancer
42. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
43. Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
44. Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor
45. Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients
46. Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?
47. AREG and EREG as Predictive Biomarkers for RAS Wild-Type Colorectal Cancer Treated With Panitumumab: A Fresh Approach to an Old Puzzle
48. Dissecting Response and Resistance to Anti–PD-1 Therapy in Microsatellite-Unstable Gastric Cancer
49. Chemoradiotherapy or Surgery for Very Early Esophageal Squamous Cancer: Can a Nonrandomized Trial Give Us the Answer?
50. A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.